Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (4090)	7/9/1998 4:10:00 PM
From: HoodBuilder	Respond to of 9523

Did you see the Viagra sales? $400 Million + for Q2 Is there any doubt this is a blockbuster drug?

To: Anthony Wong who wrote (4090)	7/9/1998 4:10:00 PM
From: MU Lation	Respond to of 9523

How does everyone think the market will take this news tomorrow? Looks like the consensus was .44. MU

To: Anthony Wong who wrote (4090)	7/9/1998 4:30:00 PM
From: BigKNY3	Read Replies (2) \| Respond to of 9523

Pfizer 2nd-Qtr Net Rises 38% on Viagra, New Antibiotic Sales New York, July 9 (Bloomberg) -- Pfizer Inc. said second- quarter profit rose 38 percent as the second-largest U.S. drugmaker introduced the first impotence pill, Viagra, to unprecedented demand. New York-based Pfizer said second-quarter profit rose to $628 million, or 47 cents a diluted share, from $457 million, or 35 cents, a year earlier. Revenue rose 25 percent to $3.63 billion from $2.91 billion after Pfizer introduced Viagra in early April. While Pfizer benefited from sales of Viagra and of a new antibiotic, Trovan, introduced in the first quarter, it suffered some setbacks in the period. The U.S. Food and Administration rejected the company's application to sell a schizophrenia drug, Zeldox, and its anti-cholesterol drugs lost more ground to competitors. It's just a phenomenal performance-- no pharmaceutical product has ever achieved $400 million in sales in its first quarter on the market,'' said Hemant Shah, an independent analyst, who has a ''neutral'' rating on Pfizer. Pfizer rose 2 1/8 to 115 5/8 in late trading. Early Viagra sales pushed Pfizer stock to a record high of 121 3/4 on April 21, letting it pass Merck & Co. briefly as the most valuable U.S. drugmaker. Pfizer last month agreed to sell one of its medical devices unit for $2.1 billion as it focuses on its more profitable drugmaking business. Pfizer's second-quarter results beat estimates of 44 cents a diluted share, the average of analysts polled by IBES International Inc.